The US Food & Drug Administration (FDA) has granted approval for Yuviwel (navepegritide) under its Accelerated Approval Program. Navepegritide is the only once-weekly treatment indicated to increase linear growth in children one years of age and older with achondroplasia with open epiphyses and the only one to provide continuous systemic exposure to CNP over the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!